March 2024 – Valerie Gharagouzloo, co-Founder at Imaginostics, is set to present at the esteemed Hello Tomorrow Global Summit in Paris, France, on March 21st-22nd, showcasing the groundbreaking QUTE-CE MRI technology that is poised to transform diagnostic imaging.

Imaginostics, a finalist in the renowned Hello Tomorrow Global Challenge, was selected from over 4,500 applicants worldwide, a testament to the innovative approach and potential impact of their QUTE-CE MRI technology. The company, under Gharagouzloo’s guidance, specializes in non-invasive, quantitative imaging technology designed to enhance vascular structure and function analysis throughout the body, with significant implications for neurology, cardiology, and oncology.

The Hello Tomorrow Global Summit is an incubator for deep tech advancements, addressing some of the most pressing global challenges through technology and innovation. This year’s summit will not only spotlight the finalists but also serve as a convergence point for industry leaders, investors, and innovators.

“Being recognized as a finalist is a monumental achievement for us,” said Gharagouzloo. “It’s a validation of our hard work and the potential of QUTE-CE MRI to revolutionize how we approach diagnostic imaging for a myriad of diseases. We’re excited to share our technology with the global community and explore partnerships that could further our impact.”

Imaginostics stands at the forefront of the Digital Health & Medical Devices category, promising a future where precise, non-invasive imaging techniques become a cornerstone of personalized medicine. The technology’s precision and its ability to provide 10X better vascular images while eliminating toxic gadolinium contrast underscore its potential to become a game-changer in the field.

The Hello Tomorrow Global Summit offers an unparalleled platform for emerging technologies, highlighting the importance of innovation in tackling health and environmental challenges. For Imaginostics, it represents an opportunity to gain visibility, attract investment, and forge partnerships that could accelerate the adoption of QUTE-CE MRI in healthcare systems worldwide.

As the summit approaches, the Imaginostics team is gearing up for what could be a pivotal moment in the company’s journey. A win at the Hello Tomorrow challenge would not only bring substantial equity-free funding but also access to a tailored coaching program and invaluable connections within the industry.

For more information about Imaginostics and the revolutionary QUTE-CE MRI technology, visit our website or follow us on social media for live updates from the Hello Tomorrow Global Summit.

In a significant stride towards transforming cancer research and treatment, Imaginostics is proud to announce its inclusion in the esteemed Paris Saclay Cancer Cluster (PSCC). This collaboration marks a pivotal moment in our ongoing mission to advance the predictive, precise, and efficient treatment of cancer through innovative technologies.

Founded under the visionary guidance of French President Emmanuel Macron in June 2021, the PSCC stands at the forefront of oncology innovation. Located in the vibrant heart of the Grand Paris area, specifically in Villejuif, the PSCC fosters a unique ecosystem where researchers, clinicians, innovators, and patients converge to accelerate breakthroughs in cancer care.

Imaginostics was one of the four new organizations announced in December to benefit from the power of the PSCC ecosystem, alongside Cherry Biotech, EverImmune, and Prostperia, Imaginostics is set to benefit from an unparalleled range of resources. This includes access to experts, networks, funding, data, samples, technologies, infrastructures, training, and laboratories. Our inclusion in this dynamic biocluster is a testament to the potential of our cutting-edge oncology projects to make a profound impact on patient care.

The Paris Saclay Cancer Cluster’s comprehensive offering aligns perfectly with our commitment to developing innovative solutions that meet the urgent needs of patients battling cancer. With the PSCC’s support, Imaginostics is poised to push the boundaries of what’s possible in oncology, leveraging our expertise to contribute to a future where cancer treatment is more targeted, effective, and compassionate.

To date, the PSCC has selected and supported 31 groundbreaking oncology projects, illustrating its pivotal role in fostering industrial development and innovation in the field. Imaginostics is honored to join this vibrant community of pioneers, and we are eager to collaborate with fellow members to advance our shared goal of transforming oncology research and treatment.

For those developing innovative solutions in oncology and interested in joining this trailblazing initiative, we encourage you to learn more about the application process at the PSCC’s website.

Imaginostics’ collaboration with the Paris Saclay Cancer Cluster heralds a new chapter in our journey to revolutionize oncology. Together, we are committed to making a lasting impact on the lives of patients around the world, pushing the envelope of innovation to fight cancer with unprecedented precision and efficacy.

Stay tuned for more updates on our projects and the groundbreaking work being done at the Paris Saclay Cancer Cluster.

Imaginostics received a notice of award on September 15^th, 2022, under the Small Business Innovation Research (SBIR) program to support a Phase I study entitled, “Validation of a Novel Magnetic Resonance Imaging (MRI) Technology for both Diagnostic Screening and Quantification of Brain Vascular Physiology in Alzheimer’s-Disease-Related Dementias.” Imaginostics is thrilled to be starting a pivotal clinical study at Brigham and Women’s Hospital (BWH) this Fall. The 96-subject study will test the ability to detect dementia early in patients with Mild Cognitive Impairment (MCI). A second arm of the study will test the ability to characterize an individual’s patients with Vascular Dementia (VaD). 

About Imaginostics:

Imaginostics, Inc., is a Boston-based longevity startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com

Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R43AG079732. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

On September 6^th, 2022, Imaginostics received a $725,000 investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support its pilot clinical study testing a novel imaging approach that can measure structure and function of the vascular system in the brain.

A significant portion of dementia cases have some aspect of cerebral small vessel disease, but current methods for quantitatively measuring vascular structure and function in living patients are limited. In their study, Imaginostics will collaborate with researchers at Harvard Medical School’s Brigham and Women’s Hospital to use their novel approach in patients with vascular dementia and mild cognitive impairment. If successful, Imaginostics would have a sensitive biomarker that could allow for earlier and more accurate diagnosis, as well as better clinical trial enrollment and outcome measurements of vascular function.

About Imaginostics:

Imaginostics, Inc., is a longevity startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com

This content is solely the responsibility of the author and does not necessarily represent the official views of the Alzheimer’s Drug Discovery Foundation.

The National Institute of Mental Health (NIMH) issued a notice of award on January 11, 2022, to Imaginostics, Inc., under the Small Business Innovation Research (SBIR) program to support a Phase I study entitled, “Development of a Frontier Magnetic Resonance (MR) Imaging Technology As a Tool for Visualization and Quantified Vascular-Feature Measurement for Use in Brain and Behavioral Research on Small Animals.” The research project aims to develop and optimize a software prototype implementing Imaginostics’ imaging technology for use with industry-standard small animal research scanners followed by testing and analytical characterization of biomarkers.

Imaginostics has brought together world-leading experts from academia and industry to accelerate drug development and understanding of the brain and mental illness by providing meaningful endpoints.

The research project reported here is supported by the National Institute of Mental Health of the National Institutes of Health under award number R43MH129045. The amount of federal funding for this project totals $436,556.

About Imaginostics:

Imaginostics, Inc., is a Boston-based health tech startup developing breakthrough magnetic resonance imaging (MRI) technology for precision medicine. It strives to create innovative, non-invasive diagnostic solutions using quantitative imaging biomarkers to provide new insight in health and disease. Its proprietary QUTE-CE (pronounced “cute-see”) MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body, providing clinicians and scientists new endpoints for early detection and enhanced characterization of complex diseases. For more information on Imaginostics, Inc., please visit: www.imaginostics.com

This content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.